This changes everything

CarryGenes’ chromosome platform will revolutionize how we treat solid cancer.

This is our vison

The next major breakthrough in immunoncology

With a proprietary human synthetic chromosome (hSynC) as a carrier for antitumoral factors (OncoSynC) introduced into the patient’s own T-cells, CarryGenes’ Cromo-T will create a state of long-term vaccination against the patient’s tumor using immune cells loaded with an enhanced tumor-killing capacity.

Read more about the method

Taking advantage of what nature is already providing

CarryGenes is a merge of technologies, a fusion of expertise in immunotherapy, biomedical sciences, and chromosome bioengineering. With a lifelong passion for science and improving human health, the team has a joint ambition to use their knowledge to help other humans.

About CarryGenes

CarryGenes in numbers



Years of experience and heritige



Phase 2/3 clinical trials



Patient-years of human safety data form post-marketing sources
No items found.